# Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

> **NCT05669742** · PHASE3 · RECRUITING · sponsor: **Tanta University** · enrollment: 40 (estimated)

## Conditions studied

- Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** olanzapine

## Key facts

- **NCT ID:** NCT05669742
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669742, "Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05669742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*